Background Hormonal contraceptives are used widely but their eff ects on HIV-1 risk are unclear. We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners.
Introduction
Safe and eff ective family planning services are central to initiatives to reduce unintended pregnancies, promote economic development, and improve the health of women and children worldwide. Among women with and at-risk for HIV-1, the prevention of unintended pregnancy is a key component of strategies to reduce vertical HIV-1 transmission. 1, 2 Hormonal contraceptive methods, including daily oral pills and long-acting injectables, are used by more than 140 million women worldwide. 3 During the past two decades, epidemiological and laboratory studies have suggested that hormonal contraception could alter the risk of HIV-1 acquisition in women. [4] [5] [6] [7] [8] However, results have been inconsistent. 9 Only one study has addressed the eff ect of hormonal contraception and risk of HIV-1 transmission from women to men. 10 Increased risk related to hormonal contraceptive use would be of importance to global public health because of the large number of women using such methods. WHO has called for high-quality studies to assess the potential role of hormonal contraception in increased HIV-1 risk.
11, 12 We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners.
Methods

Study design and participants
From 2004-10, we did two prospective studies of HIV-1 incidence in African HIV-1-serodiscordant couples (ie, one partner with HIV-1 infection and one partner without). The Partners in Prevention HSV/HIV Transmission Study was a randomised, placebocontrolled, trial of daily acyclovir herpes simplex virus type 2 (HSV-2) suppressive therapy given to 3408 people infected with HIV-1 and HSV-2 as an intervention to reduce HIV-1 transmission to their heterosexual HIV-1-seronegative partners (Clinicaltrials.gov #NCT00194519); acyclovir did not signifi cantly reduce HIV-1 transmission. 13 Couples were from seven countries in east and southern Africa (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia) and were followed for up to 24 months. In a parallel study at two of the clinical trial sites (Kampala, Uganda, and Soweto, South Africa), we enrolled an additional 485 HIV-1 serodiscordant couples into an observational study of immune correlates of HIV-1 protection and followed them for up to 12 months. For both studies, eligible participants were aged 18 years or older and sexually active, HIV-1-seropositive partners had no history of AIDS-defi ning disorders and were not using antiretroviral therapy (ART), the HIV-1-seropositive partners in the clinical trial had CD4 counts of 250 cells per μL or higher, were seropositive for HSV-2, had no known history of adverse reactions to acyclovir, and were not pregnant. Couples were recruited through study-initiated community outreach activities and referrals from HIV-1 testing and care centres, antenatal clinics, and non-governmental organisations.
14 The main reasons couples did not enrol were that they did not meet the CD4 count, HSV-2, pregnancy, or sexual activity eligibility criteria. 15 HIV-1-uninfected partners were seen quarterly for HIV-1 serological testing. For HIV-1-infected partners, CD4 counts were measured every 6 months, and participants eligible for ART initiation during follow-up were referred to local HIV-1 care clinics. All participants received comprehensive HIV-1-prevention services, including individual and couples counselling, free condoms, and treatment of sexually transmitted infections. Contraceptives were off ered by referral or on-site. Diff erences in contraceptive use occurred between sites. 16, 17 We excluded enrolled patients who were sub sequently reported to not have HSV-2 or HIV-1 infection and couples for whom the HIV-1 uninfected participant did not complete any follow-up visits for assessment of HIV-1 seroconversion. We also censored visits for couples for whom the HIV-1 infected partner started ART, because such treatment eliminated HIV-1 risk in the study population. 18 The protocols were approved by institutional review boards at the University of Washington and collaborating institutions at each study site. Participants provided written informed consent.
Procedures
Rapid HIV-1 antibody tests were used for HIV-1 serological testing and positive results were confi rmed by ELISA. 13 For HIV-1 seroconverters, analysis of HIV-1 env and gag sequences from both members of a couple was used to establish whether transmission was linked within the partnership. 19 Nucleic-acid-amplifi cation testing for bacterial sexually transmitted infections (STIs) was done on samples collected from both partners at study enrolment. 15 All participants were tested for HSV-2 with HerpeSelect-2 EIA (Focus Technologies, Cypress, CA, USA) or by HSV-specifi c western blot. 20 CD4 quantifi cation was done with standard fl ow cytometry. Plasma HIV-1 RNA concentrations were quantifi ed from a sample collected at study enrolment and 6 months later with the COBAS TaqMan real-time HIV-1 RNA assay, version 1.0 (Roche Diagnostics, Indianapolis, IN, USA). Concentrations of endocervical HIV-1 were quantifi ed with the COBAS assay of swab samples collected 6 months after enrolment from HIV-1-infected women in the clinical trial cohort, as previously detailed. 21 The lower quantifi cation limit for HIV-1 RNA testing was 240 copies.
At each quarterly study visit, women were asked about their current contraceptive method with a standard questionnaire. Women were classifi ed as exposed to hormonal contraception for each quarterly period if they reported hormonal use at the quarterly visit. Contraceptive use was analysed as a time-dependent exposure, with women assumed to have used the same method during the 3 months that elapsed between study visits. Analyses were done for exposure to any hormonal contraception and then separately for injectable and oral contraception; the comparison group was women not using hormonal contraception, which included women who had had a hysterectomy or tubal ligation, used condoms only, or used no contraception. Visits at which women reported use of implantable hormonal methods or an intrauterine device were rare (<2% of visits) and therefore excluded. Many women reported condom use, either with or without another method for contraception; condom use was thus included in analyses as a potential confounder. HIV-1-uninfected men were classifi ed as exposed to hormonal contraception if their HIV-1-infected female partner reported using an injectable or oral method at her corresponding study visit. For 4% of male follow-up time, missing contraceptive data from their female partners were imputed to be the method consistently reported at adjacent study visits; data were not imputed if methods during adjacent periods were inconsistent.
Statistical analysis
The primary outcome measure was HIV-1 seroconversion. We did separate analyses of the association of hormonal contraception with HIV-1 acquisition by women (maleto-female transmission) and HIV-1 transmission from women to men (female-to-male transmission). For female-to-male transmission, only genetically linked seroconversions were included as outcomes to minimise misclassifi cation of HIV-1 transmissions from outside partners with unknown hormonal contraceptive use, and follow-up time was censored for those men at the time they acquired HIV-1 from a partner other than the HIV-1-infected partner with whom they enrolled.
We compared participant characteristics during periods of hormonal contraceptive use and non-use with generalised estimating equations. To assess the eff ect of contraceptive method on HIV-1 risk, we used timedependent Cox proportional hazards regression with robust standard errors to account for within subject correlation with repeated measurements. 22 Models were adjusted for variables that had confounded the contraception-HIV-1-risk relation in previous analyses 7, 8 age and time-dependent pregnancy and any sex without condoms-and plasma HIV-1 concentrations in HIV-1-infected partners, a strong predictor of HIV-1 transmission. 23 We also assessed several additional variables for potential confounding: region (east Africa vs southern Africa), marital status of couples and the number of children they had together, HSV-2 status of the HIV-1-uninfected partner, circumcision status of the male partner, and STI in either partner, all recorded at study enrolment, and time-dependent measures of sexual frequency (with and without condoms), sex with additional partners, CD4 count of the HIV-1-infected partner, and genital-ulcer disease in either partner. None of these additional variables substantially (>10%) changed the eff ect estimates and thus they were not included in the fi nal multivariate models. For analysis of HIV-1 acquisition by women, we tested for eff ect modifi cation by baseline HSV-2 status and age with a likelihood-ratio test, because previous results have shown that the hormonal contraception-HIV-1-risk relation was stronger for women who were HSV-2 seronegative or who were aged less than 25 years. 24 We repeated our analyses with marginal structural modelling, a technique to adjust for time-dependent confounding. 25, 26 We computed stabilised-inverse-probability weights with logistic regression to predict the probability of hormonal contraceptive use at each visit (by concentrations of plasma HIV-1, age, region, and number of children), as described by Cole and colleagues; 27 the weights adjusted for time-dependent measures of pregnancy and unprotected sex. Weights for the eff ect of any hormonal contraception on HIV-1 risk (mean 1·00, range 0·82-1·34) were computed separately from the weights to assess the separate eff ects of injectable and oral contraception on HIV-1 risk (mean 1·07, range 0·19-4·56). These weights were then used in a pooled logistic-regression model of hormonal contraception versus HIV-1 risk.
Finally, we assessed the prevalence and quantity of genital HIV-1 RNA in women using hormonal contra ception versus those who did not by logistic and linear regression. All analyses were done with SAS 9.2.
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Results
For most of the 3790 HIV-1-serodiscordant couples included in the analysis, the HIV-1-infected partner was female (table 1) . Most couples were married with children. The median age was in the mid-30s, and 321 (24%) of 1314 uninfected women were younger than 25 years. In HIV-1-seropositive participants, the median CD4 count was 455 cells per μL (IQR 337-626) and median plasma HIV-1 RNA concentration was 4·10 log 10 copies per mL (IQR 3·37-4·73). More than a quarter of women were pregnant during study follow-up (table 1) . 27 couples enrolled in the randomised trial 13 were subsequently reported not to have HSV-2 or HIV-1 infection and were excluded from the analysis, as were 76 couples in which the HIV-1-uninfected participant did not complete any follow-up visits for assessment of HIV-1 seroconversion. For 350 couples (151 with an HIV-1-uninfected woman and 199 with an HIV-1-uninfected man) in which the HIV-1-infected partner started ART, subsequent visits were censored. Median follow-up for HIV-1-seronegative women was 18·0 (IQR 12·6-24·2) months and for seronegative men was 18·7 months (IQR 12·8-24·2). Retention at 12 months for HIV-1-seronegative women was 93% (1153 of 1238 women) and for seronegative men was 90% (2098 of 2331 men). Retention at 24 months for HIV-1-sero negative women was 87% (423 of 484 women) and for seronegative men was 84% (812 of 970 men). HIV-1-seronegative partners accrued 5157·9 personyears of follow-up for assessment of HIV-1 seroincidence, during which 167 HIV-1 seroconversions occurred. Of the 73 infections in women, 62 (85%) were determined by viral sequencing to be genetically linked within the partnership, and of the 93 infections in men, 59 (63%) were linked.
During follow-up, hormonal contraceptives were used more frequently by couples with young HIV-1-uninfected partners and couples who did not experience pregnancy (table 2) . Sexual behaviours did not diff er for HIV-1-uninfected women during periods when they were using hormonal contraception compared with when they were not using hormonal contraception. Unprotected sex was more likely and sex with an external partner was less likely for HIV-1-uninfected men, during periods when their female partner was using hormonal contraception than it was when their partner was not taking hormonal contraception. Concentrations of plasma HIV-1 RNA and Data are n/N (%) or median (IQR). *Comparisons among contraceptive-exposure groups are adjusted for correlation by multiple measures from the same woman with generalised estimating equations. The number of data points assessed for each cell is total number of visits with each covariate characteristic during study follow-up. †Contraceptive use during pregnancy intervals was either contraceptive failures documented at the time of pregnancy detection or contraceptive uptake during the early postpartum period.
Table 2: Participant characteristics during quarterly follow-up intervals with and without hormonal contraceptive use
CD4 counts were similar for hormonal-contraception exposed versus unexposed periods.
Rates of HIV-1 acquisition were higher in women using hormonal contraception than in those who were not (table 3) . In multivariate Cox proportional hazards analysis adjusted for age, pregnancy, unprotected sex, and concentrations of plasma HIV-1 in HIV-1-infected partners, use of hormonal contraceptives was associated with a two times increased risk of HIV-1 acquisition (adjusted hazard ratio 1·98, 95% CI 1·06-3·68). Increased risk was reported for both injectable (adjusted hazard ratio 2·05, 95% CI 1·04-4·04) and oral contraceptive use (1·80, 0·55-5·82), although the analysis of oral contraceptive use included only 50·5 person-years and was not statistically signifi cant. The results from the marginal structural models were generally in agreement with the Cox regression models. No evidence showed that the eff ect of hormonal contraception on HIV-1 risk was diff erent for HSV-2-seronegative women (195 [15%] of 1283) versus seropositive women (adjusted hazard ratio 1·56 vs 2·00, p interaction =0·82) or for women younger than 25 years (321 [24%] of 1314) versus those 25 years or older (adjusted hazard ratio 1·96 vs 2·21, p interaction =0·82).
The rate of HIV-1 transmission from women using hormonal contraceptives to their male partners was higher than was the rate of transmission from women who did not use hormonal contraceptives (table 4) . In multivariate analysis adjusted for age, pregnancy, unprotected sex, and concentrations of plasma HIV-1 in HIV-1-infected partners, men's HIV-1 risk was increased two times when their partners were using hormonal contraception (adjusted hazard ratio 1·97, 95% CI 1·12-3·45; table 4). Both injectable and oral contraceptive use by female partners were associated with increased HIV-1 risk for men, although the eff ect was signifi cant only for injectable contraception (table 4) . The marginal structural model analyses generated similar results to the Cox proportional hazards regression.
To account for the potential persistent biological eff ects of hormonal contraception on HIV-1 risk when women switched contraceptive methods, we assessed the eff ect of extending the exposure window for 3 months after last hormonal contraceptive use (thus, women could be exposed to more than one method during one study visit window). This assessment aff ected 32·1 (2%) of the 1782·8 person-years and one seroconversion event for the HIV-1 acquisition analysis and 70·9 (2%) of the 3375·1 personyears and one event for the female-to-male transmission analysis. The results of these analyses were not substantially diff erent than those shown in table 3  and table 4 (data not shown). When we limited the analysis of HIV-1 acquisition by women to those 62 outcomes that were genetically linked to their male partners, the eff ect estimates were not substantially changed (for any 
*Multivariate Cox proportional hazard regression model, adjusted for age, concentrations of plasma HIV-1 in the HIV-1-infected partners, and time varying unprotected sex and pregnancy. Further adjustment for additional factors did not substantially change the fi ndings. †Weighted marginal structural model is adjusted for age, region, number of children, concentration of plasma HIV-1 RNA in the HIV-1-infected partner, and month of visit (5-knot cubic spline with knots at the 5th, 25th, 50th, 75th, and 95th percentiles) and contraceptive history; weights are truncated at the 1st and 99th percentiles. 
*Multivariate Cox proportional hazard regression model, adjusted for age, plasma HIV-1 levels in the HIV-1 infected partner, and time varying unprotected sex and pregnancy. Further adjustment for additional factors did not substantially change the fi ndings. †Weighted marginal structural model is adjusted for age, region, number of children, plasma HIV-1 RNA concentration in the HIV-1 infected partner, and visit month (5-knot cubic spline with knots at the 5th, 25th, 50th, 75th and 95th percentiles) and contraceptive history; weights are truncated at the 1st and 99th percentiles. hormonal contraceptive use, Cox regression adjusted hazard ratio 2·06, 95% CI 1·05-4·03 and marginal structural model odds ratio 2·01, 95% CI 1·02-3·95). In a third sensitivity analysis, we censored observations during pregnancy and adjusted our Cox model for age, unprotected sex, and concentrations of plasma HIV-1 in HIV-1-infected partners. We did not see substantial diff erences in the eff ect estimates (Cox regression adjusted hazard ratio 1·84, 95% CI 0·97-3·49, for the association of hormonal contraception and HIV-1 acquisition among women and 1·86, 1·04-3·32, for the association of hormonal contraception and HIV-1 transmission to men) for this approach compared with our primary study models.
We measured endocervical concentrations of HIV-1 RNA from a single timepoint in 1691 HIV-1-infected women (table 5) . Women using injectable contraception at the time of endocervical-sample collection were more likely to have genital HIV-1 RNA detected than were those not using hormonal contraception. Concentrations of genital HIV-1 RNA were also higher in those using injectable contraception than in those not using hormonal contraception, by an average of 0·19 log 10 copies per swab, after adjustment for plasma HIV-1 concentrations and CD4 cell count (table 5) . No association was identifi ed between contraception and concentrations of plasma HIV-1 RNA collected at the same time as endocervical samples (median 3·91 log 10 copies per mL [IQR 3·07-4·50] for injectable users vs 4·03 log 10 copies per mL [IQR 3·22-4·65] for non-users; p=0·10), suggesting a localised eff ect of hormonal contraception on increased concentrations of HIV-1 in the female genital tract.
Discussion
Use of hormonal contraceptives was associated with a two-times increase in the risk of HIV-1 acquisition by women and HIV-1 transmission from women to men. Injectable methods were the most common form of hormonal contraception used by our study population and subgroup analyses showed signifi cantly increased HIV-1 risk associated with injectable use. Few women used oral contraceptives in our study; oral contraceptive use was associated with a non-signifi cant increase in HIV-1 risk and our results are insuffi cient for drawing defi nitive conclusions about oral contraceptive use and HIV-1 risk. Our results were robust when we adjusted for multiple potential confounding factors, undertook diff erent analytical approaches, and did sensitivity analyses.
Previous studies of HIV-1-acquisition risk related to contraceptive use have had inconsistent results, partly because of variable methodological quality. 9 As a result, public health policies-targeted risk-reduction counselling and strategies to promote alternative contraceptive methods for women with or at risk of HIV-1-have not been implemented. Our fi ndings provide new data that show that contraception might increase a woman's risk of acquiring HIV-1, and they are consistent with longitudinal studies of sex workers in Kenya and family planning attendees from Uganda and Zimbabwe. 7, 24 Moreover, to our knowledge, ours is the fi rst prospective study to show increased HIV-1 risk in male partners of HIV-1-infected women using hormonal contraception. We noted raised concentrations of HIV-1 RNA in endocervical secretions from HIV-1-infected women using injectable methods, suggesting a potential mechanism for increased risk of HIV-1 transmission. Studies of HIV-1 transmission from women to men are urgently needed to confi rm or refute our fi ndings.
Hormonal contraceptives might have physiological actions beyond pregnancy prevention, including possible risks of bone-density loss, cervical cancer, and Chlamydia trachomatis. [28] [29] [30] Clinical and laboratory studies have suggested possible mechanisms by which hormonal contraception could infl uence HIV-1 susceptibility and infectiousness including changes to vaginal structure, cytokine regulation, CCR5 expression, and cervicovaginal HIV-1 shedding. 31 Our analyses controlled for age, pregnancy, condom use, and HIV-1 concentrations in the infected partner; controlling for additional demographic, clinical, and behavioural factors did not alter our results. Only a clinical trial with random assignment of women to eff ective hormonal contraception versus non-hormonal contraception could defi nitively assess HIV-1 risk from diff erent contraceptive methods with certainty that bias in contraceptive choice and bias due to unmeasured confounding did not infl uence the results. Such a study might be diffi cult to implement because of women's preferences for diff erent contraceptive methods and the likelihood of contraceptive switching that could undermine randomisation. Limitations of our study were that contraceptive use was determined by self-report-we did not gather data on adherence to contraception, and we did not record the specifi c brand of contraception and thus cannot comment on HIV-1 risks from specifi c exogenous hormones. During the study period, low-dose combination hormonal oral contraceptives and long-acting injectable depot medroxyprogesterone acetate (DMPA) were the most commonly used methods in national family planning programmes; few studies have assessed HIV-1 risk from other injectable methods (eg, norethisterone enanthate). 12 Most participants in our study were participating in an HIV-1-prevention randomised trial and were recruited broadly from HIV-1 testing and care centres. Nearly all HIV-1-infected partners were co-infected with HSV-2; however, HSV-2 seroprevalence is more than 80% in HIV-1-infected people in sub-Saharan Africa. 32 Thus, these factors are unlikely to limit the generality of our fi ndings. We censored follow-up for those couples in which the HIV-1-infected partner initiated ART. Future studies with long post-ART follow-up should assess whether increased risk of HIV-1 acquisition and transmission occurs in the context of ART use.
Several observational studies have shown increased HIV-1 risk for women using hormonal contraceptives; 7, 24 our fi ndings suggest that male partners of HIV-1-infected women using hormonal contraception also face heightened HIV-1 risk. The benefi ts of eff ective hormonal contraceptive methods are unequivocal and must be balanced with the risk for HIV-1 infection. Our fi ndings argue for policies to counsel women about the potential for increased HIV-1 risk with hormonal contraceptive use, especially injectable DMPA use, and the importance of dual protection with condoms to decrease HIV-1 risk (panel).
Our data do not provide estimates of HIV-1 risk related to other hormonal contraceptives, such as implants, patches, or combination injectables. Data on HIV-1 risk associated with these methods and non-hormonal contraceptive methods, such as intrauterine devices, are urgently needed, and strategies to improve the accessibility and uptake of these lower-dose and non-hormonal methods should be prioritised. Contraceptive counselling should be combined with HIV-1 counselling and testing, with joint scale-up of both approaches essential for optimisation of reproductive health and HIV-1-prevention choices for women and couples. Additionally, as national HIV-1-prevention programmes begin to incorporate antiretroviral pre-exposure prophylaxis, [33] [34] [35] this new HIV-1-prevention method could be off ered to women using contraceptives or their partners.
